LLY

AI Research

EBGLYSS Phase 3 pediatric atopic dermatitis success → Zepbound pen approval near

Eli Lilly reported positive Phase 3 ADorable-1 results for EBGLYSS in pediatric moderate-to-severe atopic dermatitis, filing for label expansion. The CFO indicated that the Zepbound multi-dose pen is expected to receive FDA approval in the "next few months," which could meaningfully expand the GLP-1 weight loss product's accessibility. Despite strong pipeline progress, the stock has fallen 8% year-to-date amid sector-wide pressure on healthcare pricing, though analysts maintain an average price target north of $1,200 versus the current ~$985 level.